At this point, no one doubts that personal medicine is one of the health-related fields in which Technology, research and innovation will play a more important role.
There is no sector that is not functioning in a more or less advanced way, to equip its health system – the management of which has been transferred to regional governments – with all This sector needs to be the benchmark in the medium and long term.
Even then, Not all autonomy is following the same strategy. There are two speeds, one that has been the benchmark for some time, of those who choose to maintain this collaborative but individual work, and those of sectors that seek to gain potential by forming alliances.
[La plataforma de fabricación celular que lleva a Asturias a un nuevo nivel en el sector de la medicina personalizada]
In the first group we clearly find Navara. its internationally recognized genomic technology or its inauguration Large-scale sequencing center in the Foral community—the second publicly owned one in the whole of Spain— These are reason enough to note the development works in this area.
There are other areas that, though not because of their notoriety in personalized medicine, were characterized by them, but have fostered their strategies in individual medicine. it is case of asturiasAs D+I explained a few days ago, it has formalized the purchase of a cell manufacturing platform that will allow research and development of its own and personalized drugs.
the fact that these areas are working individually Obviously, this does not mean that they do not have open lines of cooperation with others.other territories.
What happens – and there is a difference – is it Other autonomous communities have decided to join forces with the support of the central government.
[Tecnología genómica y enfermedades raras: Navarra se vende en Brasil como líder en medicina personalizada]
Presented this week A research project on biotechnology applied to health in Castilla-La ManchaIn which seven regions participate, including Castilian-La Mancha and . Are included Andalusia, Aragon, Catalonia, Extremadura, Basque Country and Galicia.
This is a unique research project that will help build a national network of personalized medicine.
This project, titled ‘Development of tools for diagnosis, prognosis and advanced or directed therapy in personalized medicine’ It is coordinated by the Ministry of Science and Innovation and is part of the complementary schemes charged to fund the Recovery, Transformation and Resilience Plan.
The Minister of Education, Culture and Sports, Rosa Ana Rodriguez has highlighted that thanks to this initiative they are going to develop Various research programs “aimed at finding solutions from science to improve the quality of life and treatment of patients suffering from serious diseases”,
Supercomputing, Robotics or Nanotechnology
Thus, it is specified that “through the project” A large national network will be created in personalized medicine Which would allow the treatment of certain serious diseases to be adapted to the specific characteristics of each patient, thus achieving more effective treatments with fewer side effects. And Castilla-La Mancha, thanks to this initiative, will be the leading projects in this network”.
For this, Elements like biomedicine, artificial intelligence, supercomputing, robotics, sensors and nanotechnology will be combined To design and produce new diagnostic, symptomatic and therapeutic systems and devices.
“The goal is that within two or three years we have a number of drugs that can help with these treatments,” the counselor assured.
Project . embraces the importance of “Institutional Cooperation” and UCLM-related research groups participate in it, such as the Associated Neurodeath Unit, Computer Engineering, the Faculty of Medicine of Albacete and the Faculty of Environmental Sciences and Biochemistry, and SESCAM, the University Hospital of Albacete and the University Hospital of Toledo.
Castilla-La Mancha also offers patient groups (patient groups that are part of a clinical trial) In two significant pathologies: one with persistent COVID and the other with non-alcoholic fatty liver. Possible inclusion of additional groups is planned.
project is six lines of action: BERM platform (microscopy); Implementation and analysis of databases in precision medicine; Drug screening platforms and analysis of drug-target interactions; development of biological models of disease; Development of nanopharmaceuticals (coordinated by Castilla-La Mancha) and advanced medicine and medical robotics. Castilla-La Mancha research groups participate in all kinds of action.